by TractManager | Mar 30, 2017 | Clinical Utility Evaluation
This report evaluates the clinical utility of genetic testing for fragile X−associated tremor/ataxia syndrome (FXTAS). The goal of this report is to assess how genetic testing of men and women with clinical and/or radiologic features suggestive of FXTAS changes...
by TractManager | Mar 30, 2017 | Health Technology Assessment
Purpose of Technology: High-intensity focused ultrasound (HIFU) is a minimally invasive (transrectal) treatment that generates heat through sound energy to destroy tumor tissue. Sound waves produced by an ultrasonic transducer mounted on an endorectal probe penetrate...
by TractManager | Mar 30, 2017 | Health Technology Assessment
Purpose of Technology: Flow diverters are stents tunneled through blood vessels to the site of an intracranial aneurysm to block the blood vessel opening to the aneurysm. The stent diverts blood flow past the aneurysm opening, prohibiting inflow to the aneurysm, with...
by TractManager | Mar 29, 2017 | Emerging Technology Report
Zejula is an oral poly (ADP-ribose) polymerase (PARP) inhibitor. PARP inhibitors work by disabling the compromised DNA repair mechanisms of BRCA-mutated cancer cells, leading to cell death. Ovarian cancer tumors with normal BRCA genes but another homologous...
by TractManager | Mar 28, 2017 | Emerging Technology Report
Xadago is a selective, reversible MAO-B inhibitor that also inhibits release of glutamate. MAO-B inhibitors help prevent the breakdown of dopamine in the brain. Xadago is a novel reversible MAO-B inhibitor proposed as an adjunctive therapy to prolong “on” time in...
Recent Comments